Qlaris Bio is developing QLS-111, a topical ocular therapy that lowers intraocular pressure by targeting episcleral venous pressure and reducing distal outflow resistance beyond the trabecular meshwork. This approach aims to provide effective treatment for glaucoma and related conditions, achieving lower intraocular pressure targets than currently available therapies.
Funding
$49M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current glaucoma treatments often fail to achieve sufficiently low intraocular pressure (IOP), leaving patients at risk of progressive vision loss. Existing therapies primarily target the trabecular meshwork, neglecting other outflow pathways that contribute to IOP. This limitation can be particularly problematic in conditions like Normal Tension Glaucoma, Primary Open-Angle Glaucoma, and Ocular Hypertension.
Solution
Qlaris Bio is developing QLS-111, a topical ocular therapy designed to lower IOP by targeting episcleral venous pressure (EVP) and reducing distal outflow resistance beyond the trabecular meshwork. QLS-111's vasodilatory mechanism of action aims to enable the achievement of lower IOP targets than currently available therapies. By addressing EVP and distal outflow resistance, QLS-111 has the potential to provide more effective treatment for glaucoma and related conditions, including Normal Tension Glaucoma, Primary Open-Angle Glaucoma, Ocular Hypertension, and elevated IOP associated with rare diseases such as Sturge-Weber Syndrome. The therapy is currently in Phase II clinical trials.
Target Audience
The primary target audience includes patients with glaucoma and related conditions, such as Normal Tension Glaucoma, Primary Open-Angle Glaucoma, and Ocular Hypertension, who require more effective IOP lowering treatments.
Features
- Topical formulation for convenient administration
- Unique vasodilatory mechanism of action targeting episcleral venous pressure (EVP)
- Designed to reduce distal outflow resistance beyond the trabecular meshwork
- Potential to achieve lower intraocular pressure (IOP) targets compared to existing treatments
- Being investigated for the treatment of Normal Tension Glaucoma, Primary Open-Angle Glaucoma, and Ocular Hypertension
- Also being investigated for elevated IOP associated with rare diseases such as Sturge-Weber Syndrome